Summary of Conference Call Notes Company Overview - The company discussed its performance and developments related to its products, particularly focusing on CM310 (Sikukiyu monoclonal antibody), CM512 (TSLP/IL-13 dual antibody), and CMG901 (Claudin 18.2 ADC) [2][3][4][8]. Key Points Industry and Product Performance - **CM310 (Sikukiyu monoclonal antibody)**: - Achieved sales of 310 million RMB in 2025, a 77.2% increase year-on-year [3]. - Entered the national medical insurance list in January 2026, significantly boosting hospital access [4][5]. - Expected to be available in nearly 1,000 hospitals by the end of 2026, with over 40% access achieved [5]. - **CM512 (TSLP/IL-13 dual antibody)**: - Positioned as an upgraded version of CM310, with a reduced administration frequency of 2-4 injections per year [2][8]. - Clinical data for nasal polyps expected to be read out ahead of schedule in June-July 2026 [8][16]. - **CMG901 (Claudin 18.2 ADC)**: - Licensed to AstraZeneca, with global filing for second-line gastric cancer expected in H2 2026 [2][8]. - The project has entered first-line combination therapy trials, with over 2,500 patients planned for global clinical trials [10][17]. Financial Performance - Total revenue for 2025 was 720 million RMB, a 67% increase year-on-year, with product sales contributing 310 million RMB [3][11]. - The company raised 860 million HKD through H-share placement, maintaining a cash reserve of nearly 2 billion RMB by the end of 2025 [3][11]. - R&D investment remained stable at 720 million RMB, with a net loss of 500 million RMB for 2025 [11]. Production Capacity and Cost Management - The company is expanding its production capacity with the ND4 stainless steel production line, set to be operational by March 2026, which will significantly reduce costs [6][11]. R&D Pipeline and Strategic Initiatives - The company is diversifying its R&D beyond antibody drugs, with advancements in ADC, small nucleic acids, and PROTAC platforms [7][19]. - CM336 (BCMAxCD3) has shown over 90% overall response rate (ORR) and 75% complete response (CR) in multiple myeloma, with a strategic partnership with Gilead to enhance global market access [9][12]. Future Milestones - Key R&D milestones for 2026 include: - Submission of CM310 for adolescent moderate to severe atopic dermatitis [11]. - Data readout for CM512 in nasal polyps expected in mid-2026 [11]. - Initiation of clinical trials for CM313 and CMG901 [11][17]. Market Strategy and Competitive Positioning - The company aims to leverage its first-mover advantage in the dermatology field while expanding into respiratory and nasal indications [23][24]. - CM512 is not expected to be the first approved indication; instead, the focus will be on asthma and COPD to avoid pricing pressures from a large patient population [24][25]. Clinical Data and Academic Engagement - The company plans to present key clinical data at major academic conferences in 2026, including results for CM-518 and CM-310 [27]. Patient Engagement and Market Dynamics - Following the inclusion of CM310 in the national insurance list, patient adherence (DOT) has increased, with potential for over 15 treatment cycles observed in chronic patients [28]. Conclusion The company is positioned for significant growth with a robust pipeline, strategic partnerships, and a focus on expanding its market presence while maintaining financial stability and operational efficiency.

Core Viewpoint - The company reported strong revenue growth in 1H25, driven by licensing agreements and product sales, with a significant increase in income from its core product CM310 [1][2] Group 1: Financial Performance - The company achieved a revenue of 499 million yuan in 1H25, representing a year-on-year increase of 812% [1] - Product sales revenue reached 169 million yuan, while the net loss attributable to shareholders was 79 million yuan [1] - The revenue exceeded expectations primarily due to upfront payments and recent confirmations from licensing agreements for CM313 and CM355, contributing a total of 318 million yuan to the income [2] Group 2: Product Development and Market Position - CM310 has received approval for three indications: moderate to severe atopic dermatitis (AD), seasonal allergic rhinitis (SAR), and chronic rhinosinusitis with nasal polyps (CRSwNP) [1] - The sales contribution from CM310 in 1H25 was 169 million yuan, aligning with expectations [1] - The company has expanded its commercialization team to 370 members and plans to continue hiring [1] - CM310 is priced at 1,812 yuan per unit, with a promotional offer of buy two, get one free, and the company is advised to monitor the upcoming medical insurance negotiations [1] Group 3: Strategic Collaborations - The company has established a global exclusive licensing agreement with AstraZeneca for CLDN 18.2 ADC (CMG901), which is currently in a Phase III MRCT study for advanced gastric and gastroesophageal junction adenocarcinoma [2] - CM313 and CM355 have been licensed to Timberlyne and Prolium, respectively, enhancing the company's revenue through upfront and recent payments [2] - Ongoing clinical trials for CM512, CM536, and CM336 are progressing, with CM336 receiving its first overseas IND approval [2] Group 4: Profit Forecast and Valuation - The company's loss forecast for 2025 has been adjusted from 837 million yuan to 524 million yuan due to the positive impact of licensing agreements [2] - The profit forecast for 2026 remains largely unchanged [2] - The target price has been raised by 54.5% to 85.00 HKD, indicating a potential upside of 16.8% from the current stock price [2]